Toward Therapy of Human Prion Diseases - PubMed (original) (raw)
Review
Toward Therapy of Human Prion Diseases
Adriano Aguzzi et al. Annu Rev Pharmacol Toxicol. 2018.
Free article
Abstract
Three decades after the discovery of prions as the cause of Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies, we are still nowhere close to finding an effective therapy. Numerous pharmacological interventions have attempted to target various stages of disease progression, yet none has significantly ameliorated the course of disease. We still lack a mechanistic understanding of how the prions damage the brain, and this situation results in a dearth of validated pharmacological targets. In this review, we discuss the attempts to interfere with the replication of prions and to enhance their clearance. We also trace some of the possibilities to identify novel targets that may arise with increasing insights into prion biology.
Keywords: immunotherapy; luminescent polythiophene conjugates; neurodegeneration; prion; therapeutics; ubiquitin proteasome system.
Similar articles
- Rational targeting for prion therapeutics.
Mallucci G, Collinge J. Mallucci G, et al. Nat Rev Neurosci. 2005 Jan;6(1):23-34. doi: 10.1038/nrn1584. Nat Rev Neurosci. 2005. PMID: 15611724 Review. - Prion chemical biology: on the road to therapeutics?
Chen B, Thompson M, Louth J, Guo K. Chen B, et al. Curr Top Med Chem. 2013;13(19):2441-64. doi: 10.2174/15680266113136660172. Curr Top Med Chem. 2013. PMID: 24059337 Review. - [Development of molecular target based-therapy for prion diseases].
Sakasegawa Y, Doh-ura K. Sakasegawa Y, et al. Brain Nerve. 2007 Apr;59(4):405-14. Brain Nerve. 2007. PMID: 17447527 Review. Japanese. - Prions: protein aggregation and infectious diseases.
Aguzzi A, Calella AM. Aguzzi A, et al. Physiol Rev. 2009 Oct;89(4):1105-52. doi: 10.1152/physrev.00006.2009. Physiol Rev. 2009. PMID: 19789378 Review. - Prions: a mystery unravelled?
Cavallo G, Lembo D, Cavallo R. Cavallo G, et al. Riv Biol. 2010 May-Dec;103(2-3):343-70. Riv Biol. 2010. PMID: 21384329
Cited by
- Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.
Krsek A, Jagodic A, Baticic L. Krsek A, et al. Medicina (Kaunas). 2024 Aug 24;60(9):1384. doi: 10.3390/medicina60091384. Medicina (Kaunas). 2024. PMID: 39336425 Free PMC article. Review. - Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti-prion compounds.
Do K, Benavente R, Catumbela CSG, Khan U, Kramm C, Soto C, Morales R. Do K, et al. FASEB J. 2024 Jul 31;38(14):e23843. doi: 10.1096/fj.202400614R. FASEB J. 2024. PMID: 39072789 Free PMC article. - Astemizole, a Second-Generation Histamine H1-Receptor Antagonist, Did Not Attenuate the Aggregation Process of α-Synuclein In Vitro.
Choi JI, Lee H, Kim DJ, Park ES, Lee KY, Yang HJ. Choi JI, et al. Biomedicines. 2024 Mar 8;12(3):611. doi: 10.3390/biomedicines12030611. Biomedicines. 2024. PMID: 38540224 Free PMC article. - How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.
Mohapatra P, Gopikrishnan M, Doss C GP, Chandrasekaran N. Mohapatra P, et al. Int J Nanomedicine. 2024 Mar 8;19:2441-2467. doi: 10.2147/IJN.S442520. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38482521 Free PMC article. Review. - Human prion diseases and the prion protein - what is the current state of knowledge?
Nafe R, Arendt CT, Hattingen E. Nafe R, et al. Transl Neurosci. 2023 Oct 16;14(1):20220315. doi: 10.1515/tnsci-2022-0315. eCollection 2023 Jan 1. Transl Neurosci. 2023. PMID: 37854584 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources